FDA Panel Says Breast Cancer Drug Doesn't Benefit Patients

4:24 PM, Jul 20, 2010   |    comments
  • Share
  • Print
  • - A A A +

GAITHERSBURG, Md. (AP) -- Federal health advisers said overwhelmingly that the Roche drug Avastin's approval for breast cancer should be withdrawn after follow-up studies failed to show meaningful benefits for patients.

A Food and Drug Administration panel of experts voted 12-1 in favor of removing the drug's indication for use in breast cancer patients alongside chemotherapy on Tuesday.

The FDA in 2008 approved Avastin for breast cancer based on a trial showing it significantly lengthened the time until the disease worsened. But two follow-up studies recently completed by Roche failed to show the same ability to delay disease progression.

The FDA is not required to follow the panel's advice, though it often does.

Most Watched Videos